bioRxivPhysiology
Constitutive Androstane Receptor contributes towards increased drug clearance in cholestasis
B. Mathur, W. Arif, M. Patton, R. Faiyaz, A. Kalsotra, A. M. Wheatley, S. Anakk
Abstract
Understanding the alterations in drug metabolism in different liver diseases is crucial for appropriate therapeutic intervention. We performed high-throughput RNA sequencing on various liver injury models, including cholestasis, diet-induced steatosis, and regeneration. Comparative liver transcriptome analysis revealed overlapping and distinct gene profiles among different liver diseases. Particularly, cholestatic livers displayed robust induction of drug metabolizing genes. This upregulation is not a generic hepatic stress response, as it was suppressed or unchanged in other models of liver diseases. Consistently, drug metabolic gene profiles were induced in a subset of biliary atresia patients, but not in individuals with hepatitis B or C viral infection, and alcoholic hepatitis. Further analysis revealed this induction was specific to genes regulated by nuclear receptor CAR (Constitutive Androstane Receptor). To test this, we challenged cholestatic mice with a paralytic agent, zoxazolamine. Compared to controls, these mice displayed significantly reduced paralysis time, reflecting increased drug metabolism, and this effect was lost upon inhibition of CAR. Thus, CAR activation can alter therapeutic efficacy of certain drugs in a subset of cholestatic individuals.
- organism: mouse
- assay: bulk RNA-seq
- research focus: drug response / drug discovery
- research focus: gene regulatory network inference
- approach: experimental assay
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Pharmacological activation of constitutive androstane receptor induces female-specific modulation of hepatic metabolism
M. Huillet, F. Lasserre, … S. Ellero-Simatos·bioRxiv·Apr 17, 2023
- Steatotic liver disease induced by TCPOBOP-activated hepatic constitutive androstane receptor: Primary and secondary gene responses with links to disease progression
R. Sonkar, H. Ma, D. J. Waxman·bioRxiv·Feb 16, 2024
- The constitutive androstane receptor protects against metabolic dysfunction-associated steatotic liver disease through sex specific interactions with the gut microbiota
Marine Huillet, Céline M P Martin, … Sandrine Ellero‐Simatos·bioRxiv·Oct 11, 2026
- Liver lipid droplet cholesterol content is a key determinant of metabolic dysfunction-associated steatohepatitis
Ikki Sakuma, Rafael Calais Gaspar, … Gerald I. Shulman·Proceedings of the National Academy of SciencesPeer-reviewed·May 1, 2025
- GLUCURONIDATION: THE LAST DEFENSIVE LINE AGAINST BILEACID TOXICITY DURING CHOLESTASIS.
Jocelyn Trottiet, Audrey-Anne Lavoie, … Olivier Barbier·bioRxiv·Aug 23, 2025
- Regulation of gene transcription by thyroid hormone receptor β agonists in clinical development for the treatment of non-alcoholic steatohepatitis (NASH)
X. G. Luong, S. K. Stevens, … J. Deval·bioRxiv·Sep 25, 2020